Tag: FTC/DOJ Developments
2026 Antitrust Outlook: Learnings From the First Year of ‘America First’ Enforcement
Following the transition to the second Trump administration, the Department of Justice (DOJ) and Federal Trade Commission (FTC) pivoted toward a more “business-friendly” posture in many respects, while pursuing other aggressive theories of harm, reminiscent of the Biden-era antitrust enforcers. The strategic shift toward an “America First Antitrust” policy in […]
Treatment of M&A Non-solicits and Employee Comp Diligence Under New Antitrust Guidelines
Last month, the FTC and DOJ issued a set of antitrust guidelines addressing certain employment and compensation practices that are most likely to occur in the high-tech and healthcare industries where highly-skilled employees are in demand. Specifically, the guidelines clarify that an agreement among competing employers to limit or fix […]
FTC Expands HSR Reporting Obligations – Targeting Pharmaceutical Licensing Deals
A new Federal Trade Commission (“FTC”) rule, which became effective December 16, 2013, targets the pharmaceutical industry and requires Hart-Scott-Rodino Act (HSR) notices for a broader array of licensing transactions, expanding the types of deals that have to be notified to the government to allow antitrust enforcement agencies to scrutinize […]